TX-SOFTSERVE
2.12.2021 13:07:03 CET | Business Wire | Press release
SoftServe , a leading digital authority and consulting company, has released its second bi-annual Sustainability Report . The report, prepared according to GRI Standards, highlights progress made against the company’s ongoing commitment to a sustainable business strategy, featuring key initiatives and achievements that positively impact society and the environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005018/en/
“As a global organization, we must take responsibility towards our associates, customers, and communities,” said Chris Baker, CEO at SoftServe. “SoftServe is a people-centric company, focused on creating an inclusive workplace that supports our associates’ well-being, access to education, and innovation, which enables us to support sustainable development in our communities around the world.”
“In 2020 the world faced extraordinary new challenges that impacted each of us as individuals, and as a business,” said Taras Vervega, co-founder and board member at SoftServe. “It was another moment that revealed who we are as a company. The way SoftServe responded to the pandemic, the numerous solutions we have created to help our clients, and the massive response of our company and our people to help hospitals and local communities – all make me very proud of the company we’ve built.”
Diversity, Equality, and Inclusion
Since 2018, SoftServe has made significant progress towards gender equality, as the rate of women in managerial roles grew from 35% in 2018 to 49% in 2020. Additionally, as part of its inclusivity efforts, in 2020 the company launched its first learning course in accessibility testing for visually impaired people , and its graduates are now part of SoftServe’s accessibility testing team.
Advancing IT Education
Developing IT education is another focus of the company’s social initiatives. SoftServe’s IT Academy , an educational platform for students and graduates, enrolled 2,759 students and subsequently hired 1,368 graduates upon completion of its programs over the last two years. SoftServe currently maintains partnerships with 34 universities and tech schools in Ukraine, Bulgaria, and Poland, establishing new IT bachelor’s degree programs, launching tech labs, and hosting numerous educational events.
Empowering Communities
SoftServe’s approach to social responsibility includes empowering its people to give back to their communities. In 2020 SoftServe became strategic partner to UNICEF Ukraine. The parties cooperated on educational programs and initiatives in Ukraine to exchange knowledge and professional experience and worked together on several pro bono technology solutions.
Throughout 2020, SoftServe built a framework to engage associates in pro bono projects that address pressing social issues and created the company’s Open Tech crowdsourcing platform. Together with NGOs and governmental institutions, SoftServe contributed to a number of projects, including Ukraine’s National Volunteer Platform , created with UNICEF Ukraine, the Ukrainian Volunteer Service, and the Ministry of Youth and Sports of Ukraine. The Platform is an online portal that helps connect volunteers with opportunities around social assistance, education and science, culture, art, and more.
SoftServe also developed a COVID-19 triage chatbot for the Bulgarian government to provide citizens with critical information, answers to frequently asked questions, and healthcare contact information to help assess symptoms and navigate the next steps. Using advanced conversational AI, the triage chatbot quickly assesses users with a series of text or voice questions, eliminating staff burden and soothing patient fears. It is an omnichannel communication tool available on any smartphone, computer, or tablet, and can help to triage patients in under 30 seconds.
Other key social achievements include:
- 4 international awards for SoftServe’s corporate social responsibility and sustainability initiatives and projects
- 92 volunteer and charitable projects accomplished in 2019–2020
- 50+ events launched dedicated to emotional health and employee well-being
- 752 computers donated to educational establishments in 2019-2020
- 10,000+ trees planted in 2019–2020
- $882,500 contributed to projects implemented by SoftServe’s “Open Eyes” charity fund in 2019–2020
- 10+ tons of medical equipment funded via SoftServe & “Open Eyes” charity fund
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.
SoftServe delivers open innovation - from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience are built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.
Visit our website , blog , LinkedIn , Facebook , and Twitter pages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005018/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom